Skip to main navigation Skip to search Skip to main content

Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/ PALB2 mutation

  • Eileen M. O’Reilly*
  • , Jonathan W. Lee
  • , Mark Zalupski
  • , Marinela Capanu
  • , Jennifer Park
  • , Talia Golan
  • , Esther Tahover
  • , Maeve A. Lowery
  • , Joanne F. Chou
  • , Vaibhav Sahai
  • , Robin Brenner
  • , Hedy L. Kindler
  • , Kenneth H. Yu
  • , Alice Zervoudakis
  • , Shreya Vemuri
  • , Zsofia K. Stadler
  • , Richard K.G. Do
  • , Neesha Dhani
  • , Alice P. Chen
  • , David P. Kelsen
  • *Corresponding author for this work
  • Memorial Sloan-Kettering Cancer Center
  • University of Michigan, Ann Arbor
  • Sheba Medical Center at Tel Hashomer
  • Shaare Zedek Medical Center
  • Trinity College Dublin
  • The University of Chicago
  • Princess Margaret Hospital
  • National Institutes of Health

Research output: Contribution to journal › Article › peer-review

380 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/ PALB2 mutation'. Together they form a unique fingerprint.
Sort by

Keyphrases

Biochemistry, Genetics and Molecular Biology

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science